Phaseline

Companies › Beijing Health Guard Biotechnology

Beijing Health Guard Biotechnology: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Infectious disease; next expected readout Mar 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (H
Recombinant nonavalent HPV vaccine targeting 9 HPV types
HPV6, HPV11, HPV16, HPV18, HPV31Phase 3Human Papillomavirus InfectionMar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05662020Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPhase 3Human Papillomavirus InfectionInfectious diseaseMar 2028

Targets

HPV6 (1) HPV11 (1) HPV16 (1) HPV18 (1) HPV31 (1)

Companies with the same targets

Merck & Co. (MSD) Shanghai Bovax Biotechnology National Vaccine and Serum Institute, China

Companies built like this

National Vaccine and Serum Institute, China Shanghai Bovax Biotechnology CastleVax Medicago Brii Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.